YARW VYNE THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, VYNE THERAPEUTICS INC reported revenue of $97.0K (up 40.6% from a year earlier), net income of −$3.01M and diluted EPS of −$3.51; for the fiscal year ended December 2025 revenue was $570K, up 13.8% on the year before.

YARW annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $570K, gross profit n/a, operating income −$29.7M, net income −$26.5M (margin -4646.1%), EPS −$0.62
• Fiscal year ended Dec 2024: revenue $501K, gross profit n/a, operating income −$43.6M, net income −$39.8M (margin -7950.9%), EPS −$0.93
• Fiscal year ended Dec 2023: revenue $424K, gross profit n/a, operating income −$29.3M, net income −$28.5M (margin -6710.4%), EPS −$2.78
• Fiscal year ended Dec 2022: revenue $477K, gross profit n/a, operating income −$34.3M, net income −$23.2M (margin -4865.8%), EPS −$7.28
• Fiscal year ended Dec 2021: revenue $931K, gross profit n/a, operating income −$38.9M, net income −$73.3M (margin -7876.4%), EPS −$25.64

YARW quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $97.0K (up 40.6% year over year), net income −$3.01M, EPS −$3.51
• Quarter ended Mar 31, 2026: revenue $86.0K (down 57.4% year over year), net income −$3.59M, EPS −$0.08
• Quarter ended Jun 30, 2025: revenue $69.0K (down 65.2% year over year), net income −$5.76M, EPS −$6.73
• Quarter ended Mar 31, 2025: revenue $202K (up 106.1% year over year), net income −$8.61M, EPS −$0.20
• Quarter ended Dec 31, 2024 (from the annual report): revenue $84.0K (up 10.5% year over year), net income −$12.0M, EPS −$0.27
• Quarter ended Sep 30, 2024: revenue $121K (up 6.1% year over year), net income −$12.2M, EPS −$0.29
• Quarter ended Jun 30, 2024: revenue $198K (up 46.7% year over year), net income −$9.41M, EPS −$0.22
• Quarter ended Mar 31, 2024: revenue $98.0K (down 1.0% year over year), net income −$6.25M, EPS −$0.15
• Quarter ended Dec 31, 2023 (from the annual report): revenue $76.0K (up 1166.7% year over year), net income −$6.19M, EPS $4.06
• Quarter ended Sep 30, 2023: revenue $114K (down 31.7% year over year), net income −$6.58M, EPS −$2.01
• Quarter ended Jun 30, 2023: revenue $135K (up 7.1% year over year), net income −$10.1M, EPS −$3.09
• Quarter ended Mar 31, 2023: revenue $99.0K (down 44.4% year over year), net income −$5.62M, EPS −$1.74
• Quarter ended Dec 31, 2022 (from the annual report): revenue $6.00K (down 97.8% year over year), net income −$9.95M, EPS −$3.22
• Quarter ended Sep 30, 2022: revenue $167K (up 25.6% year over year), net income −$9.46M, EPS −$2.94
• Quarter ended Jun 30, 2022: revenue $126K (down 57.3% year over year), net income −$8.48M, EPS −$2.63
• Quarter ended Mar 31, 2022: revenue $178K (down 22.6% year over year), net income $4.67M, EPS $1.51
• Quarter ended Dec 31, 2021 (from the annual report): revenue $273K, net income −$11.6M, EPS −$24.42
• Quarter ended Sep 30, 2021: revenue $133K, net income −$21.3M, EPS −$0.41
• Quarter ended Jun 30, 2021: revenue $295K, net income −$19.9M, EPS −$0.39
• Quarter ended Mar 31, 2021: revenue $230K, net income −$20.6M, EPS −$0.42

YARW cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$33.1M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$34.0M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$25.3M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$29.2M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$56.4M, share buybacks n/a

YARW balance sheet

• Jun 30, 2026: cash $22.9M, total assets $23.6M, total liabilities $1.54M, shareholders' equity $22.1M
• Mar 31, 2026: cash $24.6M, total assets $25.9M, total liabilities $1.24M, shareholders' equity $24.6M
• Dec 31, 2025: cash $24.0M, total assets $30.2M, total liabilities $2.40M, shareholders' equity $27.8M
• Jun 30, 2025: cash $22.0M, total assets $44.7M, total liabilities $5.84M, shareholders' equity $38.9M
• Mar 31, 2025: cash $28.2M, total assets $56.4M, total liabilities $12.3M, shareholders' equity $44.1M
• Dec 31, 2024: cash $19.9M, total assets $66.9M, total liabilities $14.8M, shareholders' equity $52.1M
• Sep 30, 2024: cash $16.3M, total assets $76.2M, total liabilities $12.7M, shareholders' equity $63.5M
• Jun 30, 2024: cash $29.6M, total assets $86.6M, total liabilities $11.8M, shareholders' equity $74.9M

What is YARW's revenue?

VYNE THERAPEUTICS INC reported $570K of revenue for the fiscal year ended December 2025.

Is YARW profitable?

No. VYNE THERAPEUTICS INC lost $26.5M in its latest fiscal year.

YARW ownership and insider trades · All stocks